BMRN vs PLUS · P/E 40, rev $2.85B vs P/E 17, rev $2.07B
Biomarin Pharmaceutical Inc (BMRN) versus ePlus inc (PLUS) — a side-by-side from cached financials, not a winner call.
Biomarin Pharmaceutical Inc (BMRN) is a biotechnology company listed on NASDAQ.
ePlus inc (PLUS) is a software - application company listed on NASDAQ.
Latest reported BMRN revenue for 2024-12-31 was $2.85B. Net income was $426.9M. Revenue was up 18.0% from 2023-12-31 to 2024-12-31. BMRN currently screens at market cap $10.63B and trailing P/E 39.6.
Latest reported PLUS revenue for 2025-03-31 was $2.07B. Net income was $108.0M. Revenue was down 7.0% from 2024-03-31 to 2025-03-31. PLUS currently screens at market cap $2.10B and trailing P/E 17.1.
BMRN currently screens at market cap $10.63B and trailing P/E 39.6. PLUS currently screens at market cap $2.10B and trailing P/E 17.1.
Not investment advice. Open the BMRN and PLUS stock pages for the full models.
Not investment advice.